801315-74-2

Usage

Uses

Used in Pharmaceutical Synthesis:
1-Boc-4-aminoindazole is used as a synthetic intermediate for the development of new pharmaceuticals, leveraging its protective 1-Boc group to control the reactivity of the molecule during the synthesis process. This allows for the creation of a variety of drug candidates with specific therapeutic properties.
Used in Agrochemical Development:
In the agrochemical industry, 1-Boc-4-aminoindazole serves as a key intermediate in the synthesis of bioactive compounds. Its protective group enables selective reactions, which is crucial for the development of effective agrochemicals with targeted pest control or growth regulation capabilities.
Used in Organic Synthesis:
1-Boc-4-aminoindazole is utilized as a precursor in organic synthesis, where its 1-Boc group provides a means to selectively protect and manipulate the amino functionality. This selective reactivity is essential for the synthesis of complex organic molecules with specific applications in various fields, including materials science and medicinal chemistry.

InChI:InChI=1/C12H15N3O2/c1-12(2,3)17-11(16)15-10-6-4-5-9(13)8(10)7-14-15/h4-7H,13H2,1-3H3

Upstream product

• 801315-75-3 tert-butyl 4-nitro-1H-indazole-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2942-40-7 nitro-4 indazole 
• 603-83-8 3-nitro-o-tolylamine 

Relevant academic research and scientific papers

EP300/CREBBP INHIBITOR

The present invention provides a compound having excellent histone acetyltransferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

AMIDE DERIVATIVES COMPRISING HETEROCYCLOALKYL RING

PROBLEM TO BE SOLVED: To provide compounds or pharmacologically acceptable salts thereof that have excellent EP300 and/or CREBBP histone acetyltransferase inhibitory activity. SOLUTION: The invention provides compounds represented by the formula (1) in the figure or pharmacologically acceptable salts thereof. (In the formula (1), ring Q1, ring Q2, ring Q3, X and L are as defined in the specification.) SELECTED DRAWING: None COPYRIGHT: (C)2020,JPO&INPIT

Compound with dual inhibitory activity TDO, IDOO1 and application of compound for treating neurodegenerative disease (by machine translation)

The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, or a solvate thereof, which can selectively inhibit TDO, IDOO1, which has a significant inhibitory effect on TDO and/or IDOO1. In addition, the prepared compound has a remarkable anti-tumor effect, has a certain treatment effect on's disease and's disease, and has a good application prospect in the field of medicine preparation. (by machine translation)

BENZOTHIADIAZINE COMPOUNDS

The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, autoimmune diseases, infections, atherosclerosis, and ischemia-reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Synthesis of novel N-Aryl-1H-indazolamines from amino-1H-indazoles and arylboronic acids

An efficient and high-yielding synthesis of N-aryl-1H-indazolamines from amino-1H-indazole and arylboronic acids are described. In this study a series of novel N-aryl-1H-indazolamines (1a-i) were synthesized using arylboronic acids and amino-1 H-indazoles

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formulas (I), (IIA) and (IIIA) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formulas (I), (IIA) and (IIIA) and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS

There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.